Evaluation of Serum Apelin in Acute Coronary Syndrome Patients
DOI:
https://doi.org/10.32007/jfacmedbagdad.574401Keywords:
Acute Coronary Syndrome, Unstable angina, ST-segment elevation MI, Non-ST- segment elevation MI, Apelin.Abstract
Background: Acute coronary syndrome refers to any group of clinical symptoms compatible with acute myocardial ischemia including unstable angina (UA), Non-ST-segment elevation myocardial infarction (NSTEMI) & ST-segment elevation myocardial infarction (STEMI).
Apelin is a novel endogenous peptide with inotropic and vasodilatory properties, it was recently reported that serum measurements of apelin were similar to its immunohistochemical data in vessels and heart tissues.
Objectives: This study aims to evaluate serum levels of apelin in patients with Acute Coronary Syndrome related to severity of presentation.
Patients and Methods: The present study was conducted during the period from September 2014 until March 2015. Fifty-nine patients with ACS were included as (30 UA, 15 NSTEMI, & 14 STEMI) patients. Also the study included (28) apparently healthy persons served as control. Blood samples were obtained for measurements of Apelin by ELISA method.
Results: Serum apelin levels were significantly decreased in whole group of patients with ACS (1846.1±320.9) ng/ml compared to control (2719.4±272.5) ng/ml (p< 0.05). Regarding patients’ subgroups; serum apelin was lowest in STEMI (1729.0±480.0) ng/ml, NSTEMI (1816.0±289.0) ng/ml, & UA (1916.0±224.4) ng/ml when compared with control; respectively.
Conclusion: Data obtained revealed a reduction in serum apelin levels in all patients groups especially STEMI, so it could be considered as a biochemical marker for evaluation of ACS.
Downloads
Downloads
Published
Issue
Section
License
Permit others to copy and distribute the manuscript; to extract, revise, and create another derivative
works of or from the manuscript (e.g., a translation); to incorporate the manuscript into a
collective work; and to text or data mine the article, even for commercial purposes, provided that
the author(s) is/are credited; the article's modifications should not harm the author's honor or
reputation; and the article should not be altered in a way that would cause the author to lose them
reputation. The Creative Commons Attribution 4.0 International License (CC BY 4.0) has more
information.
How to Cite
Creative Commons Attribution 4.0 International license..
